First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection Alphyn Biologics is a clinical-stage ...

Alphyn Capital Management stated the following regarding Alphabet Inc. (NASDAQ:GOOG) in its Q4 2024 investor letter: "Alphabet Inc.'s (NASDAQ:GOOG) recent earnings demonstrated solid financial ...

"The initiation of patient dosing in our CLEAR-AD1 Phase 2b clinical trial is another significant milestone for Alphyn, as we strive to bring to market our single comprehensive treatment for ...

April 8, 2025 /PRNewswire/ -- Alphyn , a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ®, announced today that the first patient has been dosed in its ...

First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection Alphyn Biologics is a clinical-stage dermatology ...